Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Page 1
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. Harrington KJ, et al. Among authors: hughes bgm. J Clin Oncol. 2023 Feb 1;41(4):790-802. doi: 10.1200/JCO.21.02508. Epub 2022 Oct 11. J Clin Oncol. 2023. PMID: 36219809 Free PMC article. Clinical Trial.
PURPOSE: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented. ...
PURPOSE: Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in …
Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment.
Ahern E, Brown TE, Campbell L, Hughes BGM, Banks M, Lin CY, Kenny LM, Bauer J. Ahern E, et al. Among authors: hughes bgm. Br J Nutr. 2023 Feb 14;129(3):406-415. doi: 10.1017/S0007114522000435. Epub 2022 Feb 14. Br J Nutr. 2023. PMID: 35152926 Free PMC article.
Post-treatment sarcopenia should be evaluated as an independent risk factor for decreased long-term survival post-treatment containing radiotherapy (RT) for HNSCC....
Post-treatment sarcopenia should be evaluated as an independent risk factor for decreased long-term survival post-treatment containin …
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Rischin D, et al. Among authors: hughes bgm. J Immunother Cancer. 2021 Aug;9(8):e002757. doi: 10.1136/jitc-2021-002757. J Immunother Cancer. 2021. PMID: 34413166 Free PMC article. Clinical Trial.
BACKGROUND: To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC), and to determine duration of response (DOR) and impact on quality of life (QoL). ...
BACKGROUND: To provide pooled longer term data from three groups of a phase 2 study of cemiplimab in patients with advanced cutaneous …
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E, Solomon BJ, Hui R, Pavlakis N, O'Byrne K, Hughes BGM. Ahern E, et al. Among authors: hughes bgm. J Immunother Cancer. 2021 Jun;9(6):e002248. doi: 10.1136/jitc-2020-002248. J Immunother Cancer. 2021. PMID: 34083418 Free PMC article. Review.
Preclinical studies in mouse cancer models support the proof of concept of neoadjuvant ICI (NAICI) through improvement of T-cell effector function and long-term memory induction. Preliminary early-phase human trial data support the proposition that NAICI in NSCLC may provi …
Preclinical studies in mouse cancer models support the proof of concept of neoadjuvant ICI (NAICI) through improvement of T-cell effector fu …
Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients.
Kulasinghe A, Taheri T, O'Byrne K, Hughes BGM, Kenny L, Punyadeera C. Kulasinghe A, et al. Among authors: hughes bgm. Front Oncol. 2021 Jan 19;10:607349. doi: 10.3389/fonc.2020.607349. eCollection 2020. Front Oncol. 2021. PMID: 33542903 Free PMC article.
BACKGROUND: Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell carcinoma (HNSCC) patients. ...
BACKGROUND: Immune checkpoint inhibitors (ICI) have shown durable and long-term benefits in a subset of head and neck squamous cell c …
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Rischin D, et al. Among authors: hughes bgm. J Immunother Cancer. 2020 Jun;8(1):e000775. doi: 10.1136/jitc-2020-000775. J Immunother Cancer. 2020. PMID: 32554615 Free PMC article. Clinical Trial.
Here we report the primary analysis of fixed dose cemiplimab 350 mg intravenously every 3 weeks (Q3W) (Group 3) and provide a longer-term update after the primary analysis of weight-based cemiplimab 3 mg/kg intravenously every 2 weeks (Q2W) (Group 1) among metastatic CSCC …
Here we report the primary analysis of fixed dose cemiplimab 350 mg intravenously every 3 weeks (Q3W) (Group 3) and provide a longer-term …
Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE).
Ahern E, Allen MJ, Schmidt A, Lwin Z, Hughes BGM. Ahern E, et al. Among authors: hughes bgm. Asia Pac J Clin Oncol. 2021 Apr;17(2):e109-e116. doi: 10.1111/ajco.13350. Epub 2020 Jun 9. Asia Pac J Clin Oncol. 2021. PMID: 32519444
In those patients, commencement of corticosteroids was delayed (1.5 days, P = 0.01) but this did not translate into adverse outcomes such as prolonged admissions, prolonged steroid use or long-term complications. All patients with irAE were managed with high-dose corticost …
In those patients, commencement of corticosteroids was delayed (1.5 days, P = 0.01) but this did not translate into adverse outcomes such as …
Impact of early prophylactic feeding on long term tube dependency outcomes in patients with head and neck cancer.
Brown T, Banks M, Hughes BGM, Lin C, Kenny LM, Bauer JD. Brown T, et al. Among authors: hughes bgm. Oral Oncol. 2017 Sep;72:17-25. doi: 10.1016/j.oraloncology.2017.06.025. Epub 2017 Jul 5. Oral Oncol. 2017. PMID: 28797454 Clinical Trial.
This study aimed to determine whether early feeding via PGT impacted on longer term tube feeding outcomes. MATERIALS AND METHODS: Patients with HNSCC with PGT were observed monthly post-treatment regarding tube use and time to removal up to twelve months. ...Encouraging ea …
This study aimed to determine whether early feeding via PGT impacted on longer term tube feeding outcomes. MATERIALS AND METHODS: Pat …
New radiotherapy techniques do not reduce the need for nutrition intervention in patients with head and neck cancer.
Brown T, Banks M, Hughes BG, Lin C, Kenny LM, Bauer JD. Brown T, et al. Among authors: hughes bg. Eur J Clin Nutr. 2015 Oct;69(10):1119-24. doi: 10.1038/ejcn.2015.141. Epub 2015 Aug 26. Eur J Clin Nutr. 2015. PMID: 26306565
Helical intensity-modulated radiotherapy (H-IMRT) delivered by Tomotherapy, is an advanced radiotherapy technique introduced at our centre in 2010. This form of therapy reduces long-term treatment-related toxicity to normal tissues. The aim of this study is to compare weig …
Helical intensity-modulated radiotherapy (H-IMRT) delivered by Tomotherapy, is an advanced radiotherapy technique introduced at our centre i …
Swallowing outcomes and PEG dependence in head and neck cancer patients receiving definitive or adjuvant radiotherapy +/- chemotherapy with a proactive PEG: a prospective study with long term follow up.
Crombie JM, Ng S, Spurgin AL, Ward EC, Brown TE, Hughes BG. Crombie JM, et al. Among authors: hughes bg. Oral Oncol. 2015 Jun;51(6):622-8. doi: 10.1016/j.oraloncology.2015.03.006. Epub 2015 Apr 10. Oral Oncol. 2015. PMID: 25865554
OBJECTIVES: This study examined long term swallowing outcomes of a cohort of head and neck cancer (HNC) patients identified at high risk of experiencing significant side effects from cancer treatment and were provided with a proactive PEG. ...CONCLUSION: Proactive PEG plac …
OBJECTIVES: This study examined long term swallowing outcomes of a cohort of head and neck cancer (HNC) patients identified at high r …